{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:59Z","timestamp":1791488279952,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-003"],"award-info":[{"award-number":["2021-I2M-1-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-A-003"],"award-info":[{"award-number":["T-A-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HR2020MS-0415"],"award-info":[{"award-number":["Y-HR2020MS-0415"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HR2020QN-0414"],"award-info":[{"award-number":["Y-HR2020QN-0414"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HR2019-0239"],"award-info":[{"award-number":["Y-HR2019-0239"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["2023ZD0502400"],"award-info":[{"award-number":["2023ZD0502400"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["BJYAYY-YN2024-18"],"award-info":[{"award-number":["BJYAYY-YN2024-18"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jare.2025.08.016","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:29:27Z","timestamp":1755041367000},"page":"775-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers"],"prefix":"10.1016","volume":"83","author":[{"given":"Chengpei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilun","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taifeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2025.08.016_b0005","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.08.016_b0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2025.08.016_b0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2022.11.005","article-title":"Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma","volume":"78","author":"Merters","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2025.08.016_b0020","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.08.016_b0025","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities. version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jare.2025.08.016_b0030","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jare.2025.08.016_b0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0060","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death Protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","volume":"11","author":"Ng","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jare.2025.08.016_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor\u2013treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40364-024-00607-8","article-title":"Gut microbiota and metabolites signatures of clinical response in anti-PD-1\/PD-L1 based immunotherapy of biliary tract cancer","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.jare.2025.08.016_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008686","article-title":"Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.08.016_b0095","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.jare.2025.08.016_b0105","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/j.annonc.2022.07.897","article-title":"Correlation of gut microbiome composition with checkpoint inhibitor induced severe immune-related adverse events","volume":"33","author":"Verheijden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0110","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1093\/bioinformatics\/btaa276","article-title":"aPCoA: covariate adjusted principal coordinates analysis","volume":"36","author":"Shi","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jare.2025.08.016_b0115","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2025.08.016_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.08.016_b0125","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2025.08.016_b0130","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2666-5247(22)00203-8","article-title":"The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly","volume":"3","author":"Zhang","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jare.2025.08.016_b0135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ccell.2021.07.002","article-title":"Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy","volume":"39","author":"Shiao","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2025.08.016_b0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s40168-023-01586-y","article-title":"Enterotypes of the human gut mycobiome","volume":"11","author":"Lai","year":"2023","journal-title":"Microbiome"},{"key":"10.1016\/j.jare.2025.08.016_b0145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cell.2021.01.016","article-title":"Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies","volume":"184","author":"Doron","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jare.2025.08.016_b0150","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/gutjnl-2021-326298","article-title":"Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health","volume":"71","author":"Shuai","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jare.2025.08.016_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.620943","article-title":"Bacteroides thetaiotaomicron ameliorates experimental allergic airway inflammation via activation of ICOS+Tregs and inhibition of Th2 response","volume":"12","author":"Pang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.08.016_b0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4049\/jimmunol.2200892","article-title":"The NQR complex regulates the immunomodulatory function of Bacteroides thetaiotaomicron","volume":"211","author":"Engelhart","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2025.08.016_b0165","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2025.08.016_b0170","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2236750","article-title":"Fecal virome transplantation is sufficient to alter fecal microbiota and drive lean and obese body phenotypes in mice","volume":"15","author":"Borin","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jare.2025.08.016_b0175","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1038\/s41467-018-06103-6","article-title":"Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection","volume":"9","author":"Zuo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2025.08.016_b0180","article-title":"Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.08.016_b0185","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3389\/fmicb.2017.01287","article-title":"Oral probiotics alter healthy feline respiratory microbiota","volume":"8","author":"Vient\u00f3s-Plotts","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jare.2025.08.016_b0190","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2022.0494","article-title":"The potential of the gut microbiome to reshape the cancer therapy paradigm: a review","volume":"8","author":"Liu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0195","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1634\/theoncologist.2017-0531","article-title":"Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy","volume":"23","author":"Parakh","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2025.08.016_b0205","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune\u2010related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jare.2025.08.016_b0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2025.08.016_b0220","doi-asserted-by":"crossref","DOI":"10.1007\/s43657-024-00193-7","article-title":"Precision dietary intervention: gut microbiome and meta-metabolome as functional readouts","author":"Luo","year":"2025","journal-title":"Phenomics"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225006058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225006058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:03:47Z","timestamp":1778835827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225006058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"alternative-id":["S2090123225006058"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.08.016","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}